Picosulfuric acid

Identification

Name

Picosulfuric acid

Accession Number

DB09268

Type

Small Molecule

Groups

Approved

Description

Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years ^[4].

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for DB09268 (Picosulfuric acid)

×

Close

Synonyms

• Picosulfate
• Picosulphate

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Sodium picosulfate	VW106606Y8	10040-45-6	GOZDTZWAMGHLDY-UHFFFAOYSA-L
Sodium picosulfate monohydrate	LR57574HN8	1307301-38-7	FHYUVJHZGPGDSP-UHFFFAOYSA-L

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Citracleen	Sodium picosulfate (10 mg) + Citric Acid (10.97 g) + Magnesium oxide (3.5 g)	Powder, for solution	Oral	Laboratorios Casen Fleet, S.L.U.	Not applicable	Not applicable
Clenpiq	Sodium picosulfate (10 mg/160mL) + Citric Acid (12 g/160mL) + Magnesium oxide (3.5 g/160mL)	Liquid	Oral	Ferring Pharmaceuticals	2017-11-28	Not applicable
Oral Purgative	Sodium picosulfate (10 mg) + Citric Acid (12 g) + Magnesium oxide (3.5 g)	Powder, for solution	Oral	Odan Laboratories Ltd	2011-11-16	2017-06-22
Pico-salax	Sodium picosulfate (10 mg) + Citric Acid (12 g) + Magnesium oxide (3.5 g)	Powder, for solution	Oral	Ferring Pharmaceuticals	2004-11-25	Not applicable
Picodan	Sodium picosulfate (10 mg) + Citric Acid (12 g) + Magnesium oxide (3.5 g)	Powder, for solution	Oral	Odan Laboratories Ltd	2007-10-17	2012-12-31
Picoflo	Sodium picosulfate (10 mg) + Citric Acid (12 g) + Magnesium oxide (3.5 g)	Powder, for solution	Oral	Pharmascience Inc	2011-03-25	Not applicable
Prepopik	Sodium picosulfate (10 mg/16.2g) + Citric Acid (12 g/16.2g) + Magnesium oxide (3.5 g/16.2g)	Powder, metered	Oral	Ferring Pharmaceuticals	2014-09-05	Not applicable
Prepopik	Sodium picosulfate (10 mg/16.1g) + Citric Acid (12 g/16.1g) + Magnesium oxide (3.5 g/16.1g)	Powder, metered	Oral	Ferring Pharmaceuticals	2012-07-16	Not applicable
Purg-odan	Sodium picosulfate (10 mg) + Citric Acid (12 g) + Magnesium oxide (3.5 g)	Powder, for solution	Oral	Odan Laboratories Ltd	2009-02-16	Not applicable

International/Other Brands

Guttalax / Laxoberal / Laxoberon / Namilax / Pico-Salax / Picolax / Picoprep / Prepopik / Purg-Odan / Sodipic Picofast

Categories

• Acids, Acyclic
• Alimentary Tract and Metabolism
• Contact Laxatives
• Drugs for Constipation
• Gastrointestinal Agents
• Laxatives
• Pyridines
• Tricarboxylic Acids

UNII

95D580798S

CAS number

10040-34-3

Weight

Average: 437.44
Monoisotopic: 437.023908795

Chemical Formula

C₁₈H₁₅NO₈S₂

InChI Key

UJIDKYTZIQTXPM-UHFFFAOYSA-N

InChI

InChI=1S/C18H15NO8S2/c20-28(21,22)26-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(11-7-14)27-29(23,24)25/h1-12,18H,(H,20,21,22)(H,23,24,25)

IUPAC Name

{4-[(pyridin-2-yl)[4-(sulfooxy)phenyl]methyl]phenyl}oxidanesulfonic acid

SMILES

OS(=O)(=O)OC1=CC=C(C=C1)C(C1=CC=C(OS(O)(=O)=O)C=C1)C1=CC=CC=N1

Pharmacology

Indication

Indicated for cleansing of the colon as a preparation for colonoscopy in adults ^[Label].

Associated Therapies

• Bowel preparation therapy

Pharmacodynamics

Sodium picosulfate is a stimulant laxative that in conjunction with magnesium citrate, produces a purgative effect on stools. In a multicentre, observational study comprising of patients undergoing colonoscopy, more than 93.0% of the patients receiving sodium picosulfate-containing preparations reported the colon cleansing effect to be effective ^[4].

Mechanism of action

Picosulfuric acid, as sodium picosulfate, is a contact laxative. Sodium picosulfate inhibits the absorption of water and electrolytes, and increases their secretion into the intestinal lumen ^[3]. It is hydrolyzed by colonic bacterial enzyme, sulfatase ^[3], to form an active metabolite bis-(p-hydroxy-phenyl)-pyridyl-2-methane (BHPM), which acts directly on the colonic mucosa to stimulate colonic peristalsis ^[Label].

Absorption

In healthy volunteers receiving 2 packets of sodium picosulfate in combination with magnesium oxide and anhydrous citric acid every 6 hours, the mean peak plasma concentrations (Cmax) of sodium picosulfate was achieved within 7 hours (Tmax) ^[Label]. The mean Cmax of its active metabolite, BHPM, was 0.05 ng/mL ^[Label].

Volume of distribution

No pharmacokinetic data is available for picosulfuric acid.

Protein binding

No pharmacokinetic data is available for picosulfuric acid.

Metabolism

Sodium picosulfate is hydrolyzed by colonic bacteria to form an active metabolite bis-(p-hydroxy-phenyl)-pyridyl-2-methane (BHPM) ^[Label].

Route of elimination

Sodium picosulfate and its metabolite BHPM are mainly excreted in urine. The fraction of the absorbed sodium picosulfate dose excreted in urine as unchanged parent compound was 0.19% ^[Label]. Urinary recovery of BHPM was 0.01% of total administered drug ^[Label]. A small amount absorbed picosulfate is reported to be excreted in the urine as a glucuronide-conjugate of BHPM ^[5].

Half life

The terminal half-life of sodium picosulfate was 7.4 hours ^[Label].

Clearance

No pharmacokinetic data is available for picosulfuric acid.

Toxicity

Overdosage of laxative preparations containing sodium picosulfate may lead to severe electrolyte disturbances, in addition to dehydration and hypovolemia, with signs and symptoms of these disturbances. In case of overdose, monitor for fluid and electrolyte disturbances with symptomatic treatment ^[Label]. In vitro, 800 and 1600 mg/mL of sodium picosulfate exerted cytotoxic effects on cultured liver cells by inducing dose-dependent vacuolic and fatty change, as well as necrosis combined with a lowered mitotic activity and a slight increase in LDH values of the rapidly growing cultured liver cells of rabbit ^[1].

Affected organisms

• Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
Amdinocillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Amdinocillin.	Investigational, Withdrawn
Amikacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Amikacin.	Approved, Investigational, Vet Approved
Aminosalicylic Acid	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Aminosalicylic Acid.	Approved
Amithiozone	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Amithiozone.	Investigational
Amoxicillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Amoxicillin.	Approved, Vet Approved
Amphotericin B	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Amphotericin B.	Approved, Investigational
Ampicillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ampicillin.	Approved, Vet Approved
Amprenavir	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Amprenavir.	Approved, Investigational
Anisomycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Anisomycin.	Experimental
Apramycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Apramycin.	Experimental, Vet Approved
Aurodox	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Aurodox.	Experimental
Avibactam	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Avibactam.	Approved
Avilamycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Avilamycin.	Vet Approved
Azidamfenicol	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Azidamfenicol.	Experimental
Azithromycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Azithromycin.	Approved
Azlocillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Azlocillin.	Approved
Aztreonam	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Aztreonam.	Approved
Bacampicillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Bacampicillin.	Approved, Investigational
Bacitracin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Bacitracin.	Approved, Vet Approved
Bambermycins	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Bambermycins.	Vet Approved
Bedaquiline	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Bedaquiline.	Approved
Bekanamycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Bekanamycin.	Experimental
Benzylpenicillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Benzylpenicillin.	Approved, Vet Approved
Besifloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Besifloxacin.	Approved
Brefeldin A	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Brefeldin A.	Experimental
Candicidin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Candicidin.	Withdrawn
Capreomycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Capreomycin.	Approved
Carbenicillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Carbenicillin.	Approved, Investigational
Carbenicillin indanyl	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Carbenicillin indanyl.	Approved, Investigational
Carfecillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Carfecillin.	Experimental
Cefacetrile	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefacetrile.	Approved
Cefaclor	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefaclor.	Approved
Cefadroxil	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefadroxil.	Approved, Vet Approved, Withdrawn
Cefalotin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefalotin.	Approved, Investigational, Vet Approved
Cefamandole	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefamandole.	Approved, Investigational
Cefapirin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefapirin.	Approved, Vet Approved
Cefatrizine	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefatrizine.	Experimental
Cefazedone	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefazedone.	Experimental
Cefazolin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefazolin.	Approved
Cefdinir	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefdinir.	Approved
Cefditoren	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefditoren.	Approved, Investigational
Cefepime	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefepime.	Approved, Investigational
Cefetamet	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefetamet.	Experimental
Cefixime	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefixime.	Approved, Investigational
Cefmenoxime	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefmenoxime.	Approved
Cefmetazole	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefmetazole.	Approved, Investigational
Cefminox	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefminox.	Approved
Cefodizime	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefodizime.	Experimental
Cefonicid	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefonicid.	Approved, Investigational
Cefoperazone	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefoperazone.	Approved, Investigational
Ceforanide	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceforanide.	Approved
Cefotaxime	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefotaxime.	Approved
Cefotetan	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefotetan.	Approved
Cefotiam	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefotiam.	Approved, Investigational
Cefoxitin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefoxitin.	Approved
Cefpiramide	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefpiramide.	Approved
Cefpirome	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefpirome.	Approved
Cefpodoxime	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefpodoxime.	Approved, Vet Approved
Cefprozil	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefprozil.	Approved
Cefradine	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefradine.	Approved
Cefsulodin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefsulodin.	Experimental
Ceftazidime	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftazidime.	Approved
Ceftezole	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftezole.	Experimental
Ceftibuten	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftibuten.	Approved, Investigational
Ceftiofur	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftiofur.	Vet Approved
Ceftizoxime	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftizoxime.	Approved, Investigational
Ceftobiprole	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftobiprole.	Approved, Investigational
Ceftriaxone	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftriaxone.	Approved
Cefuroxime	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefuroxime.	Approved
Cephalexin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cephalexin.	Approved, Investigational, Vet Approved
Cephaloglycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cephaloglycin.	Approved
Cephaloridine	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cephaloridine.	Approved, Withdrawn
Cethromycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cethromycin.	Investigational
Chloramphenicol	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Chloramphenicol.	Approved, Vet Approved
Chloramphenicol succinate	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Chloramphenicol succinate.	Experimental
Chloroxine	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Chloroxine.	Approved
Chlortetracycline	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Chlortetracycline.	Approved, Investigational, Vet Approved
Ciprofloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ciprofloxacin.	Approved, Investigational
Clarithromycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Clarithromycin.	Approved
Clavulanate	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Clavulanate.	Approved, Vet Approved
Clinafloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Clinafloxacin.	Investigational
Clindamycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Clindamycin.	Approved, Vet Approved
Clofazimine	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Clofazimine.	Approved, Investigational
Cloxacillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cloxacillin.	Approved, Investigational, Vet Approved
Colistin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Colistin.	Approved
Cyclacillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cyclacillin.	Approved
Cycloserine	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cycloserine.	Approved
Dactinomycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Dactinomycin.	Approved, Investigational
Dalbavancin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Dalbavancin.	Approved, Investigational
Dalfopristin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Dalfopristin.	Approved
Dapsone	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Dapsone.	Approved, Investigational
Daptomycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Daptomycin.	Approved, Investigational
Decamethoxine	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Decamethoxine.	Experimental
Demeclocycline	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Demeclocycline.	Approved
Dibekacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Dibekacin.	Experimental
Dicloxacillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Dicloxacillin.	Approved, Investigational, Vet Approved
Dihydrostreptomycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Dihydrostreptomycin.	Investigational, Vet Approved
Dirithromycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Dirithromycin.	Approved, Investigational
Doxycycline	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Doxycycline.	Approved, Investigational, Vet Approved
Efrotomycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Efrotomycin.	Vet Approved
Enoxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Enoxacin.	Approved, Investigational
Enviomycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Enviomycin.	Approved
Epetraborole	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Epetraborole.	Investigational
Epicillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Epicillin.	Experimental
Ertapenem	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ertapenem.	Approved, Investigational
Erythromycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Erythromycin.	Approved, Investigational, Vet Approved
Ethambutol	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ethambutol.	Approved
Ethionamide	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ethionamide.	Approved
Fidaxomicin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Fidaxomicin.	Approved
Finafloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Finafloxacin.	Approved, Investigational
Florfenicol	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Florfenicol.	Vet Approved
Flucloxacillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Flucloxacillin.	Approved, Investigational
Fosfomycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Fosfomycin.	Approved
Framycetin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Framycetin.	Approved
Fumagillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Fumagillin.	Experimental
Fusafungine	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Fusafungine.	Approved, Withdrawn
Fusidic Acid	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Fusidic Acid.	Approved, Investigational
Gamithromycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Gamithromycin.	Vet Approved
Garenoxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Garenoxacin.	Investigational
Gatifloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Gatifloxacin.	Approved, Investigational
GE-2270A	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with GE-2270A.	Experimental
Gemifloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Gemifloxacin.	Approved, Investigational
Gentamicin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Gentamicin.	Approved, Vet Approved
Gramicidin D	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Gramicidin D.	Approved
Grepafloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Grepafloxacin.	Approved, Investigational, Withdrawn
Griseofulvin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Griseofulvin.	Approved, Investigational, Vet Approved
Hachimycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Hachimycin.	Experimental
Hygromycin B	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Hygromycin B.	Vet Approved
Imipenem	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Imipenem.	Approved
Isatoic anhydride	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Isatoic anhydride.	Experimental
Isepamicin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Isepamicin.	Experimental
Isoniazid	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Isoniazid.	Approved, Investigational
Josamycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Josamycin.	Approved, Investigational
Kanamycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Kanamycin.	Approved, Investigational, Vet Approved
Kitasamycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Kitasamycin.	Experimental
Lanopepden	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Lanopepden.	Investigational
Lasalocid	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Lasalocid.	Vet Approved
Latamoxef	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Latamoxef.	Approved, Investigational
Levofloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Levofloxacin.	Approved, Investigational
Lincomycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Lincomycin.	Approved, Vet Approved
Linezolid	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Linezolid.	Approved, Investigational
Lomefloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Lomefloxacin.	Approved, Investigational
Loracarbef	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Loracarbef.	Investigational, Withdrawn
Lymecycline	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Lymecycline.	Approved, Investigational
Maduramicin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Maduramicin.	Vet Approved
Maltotetraose	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Maltotetraose.	Experimental
Marbofloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Marbofloxacin.	Vet Approved
Mepartricin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mepartricin.	Experimental
Meropenem	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Meropenem.	Approved, Investigational
Metampicillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Metampicillin.	Experimental
Methacycline	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Methacycline.	Approved, Investigational
Meticillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Meticillin.	Approved, Investigational
Metronidazole	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Metronidazole.	Approved
Mevastatin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mevastatin.	Experimental
Mezlocillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mezlocillin.	Approved, Investigational
Micronomicin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Micronomicin.	Experimental
Midecamycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Midecamycin.	Approved
Miglitol	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Miglitol.	Approved
Minocycline	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Minocycline.	Approved, Investigational
Miocamycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Miocamycin.	Experimental
Mizoribine	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mizoribine.	Investigational
Moxifloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Moxifloxacin.	Approved, Investigational
Mupirocin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mupirocin.	Approved, Investigational, Vet Approved
Nadifloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Nadifloxacin.	Investigational
Nafcillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Nafcillin.	Approved, Investigational
Nalidixic Acid	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Nalidixic Acid.	Approved, Investigational
Narasin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Narasin.	Vet Approved
Natamycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Natamycin.	Approved
Nebularine	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Nebularine.	Experimental
Neomycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Neomycin.	Approved, Vet Approved
Netilmicin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Netilmicin.	Approved, Investigational
Norfloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Norfloxacin.	Approved
Novobiocin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Novobiocin.	Approved, Investigational, Vet Approved
Nystatin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Nystatin.	Approved, Vet Approved
Ofloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ofloxacin.	Approved
Oleandomycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Oleandomycin.	Vet Approved
Oritavancin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Oritavancin.	Approved, Investigational
Oxacillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Oxacillin.	Approved, Investigational
Oxolinic acid	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Oxolinic acid.	Experimental
Oxytetracycline	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Oxytetracycline.	Approved, Investigational, Vet Approved
Ozenoxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ozenoxacin.	Approved, Investigational
Paromomycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Paromomycin.	Approved, Investigational
Pazufloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Pazufloxacin.	Investigational
Pecilocin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Pecilocin.	Experimental
Pefloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Pefloxacin.	Approved
Penimepicycline	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Penimepicycline.	Experimental
Pentamycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Pentamycin.	Experimental
Phenoxymethylpenicillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Phenoxymethylpenicillin.	Approved, Vet Approved
Phosphoramidon	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Phosphoramidon.	Experimental
Pipemidic acid	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Pipemidic acid.	Experimental
Piperacillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Piperacillin.	Approved
Pivampicillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Pivampicillin.	Approved
Pivmecillinam	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Pivmecillinam.	Approved
Polymyxin B Sulfate	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Polymyxin B Sulfate.	Approved, Vet Approved
Pristinamycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Pristinamycin.	Experimental, Investigational
Procaine benzylpenicillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Procaine benzylpenicillin.	Approved, Vet Approved
Propicillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Propicillin.	Experimental
Protionamide	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Protionamide.	Approved, Investigational
Prulifloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Prulifloxacin.	Investigational
Pyrazinamide	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Pyrazinamide.	Approved, Investigational
Pyrrolnitrin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Pyrrolnitrin.	Experimental
Quinupristin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Quinupristin.	Approved
Ramoplanin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ramoplanin.	Investigational
Relebactam	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Relebactam.	Investigational
Retapamulin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Retapamulin.	Approved
Ribostamycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ribostamycin.	Approved, Investigational
Rifabutin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Rifabutin.	Approved, Investigational
Rifalazil	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Rifalazil.	Investigational
Rifampicin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Rifampicin.	Approved
Rifapentine	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Rifapentine.	Approved, Investigational
Rifaximin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Rifaximin.	Approved, Investigational
Rolitetracycline	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Rolitetracycline.	Approved
Roxarsone	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Roxarsone.	Vet Approved
Roxithromycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Roxithromycin.	Approved, Investigational, Withdrawn
Salinomycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Salinomycin.	Vet Approved
Sirolimus	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sirolimus.	Approved, Investigational
Sisomicin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sisomicin.	Investigational
Sitafloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sitafloxacin.	Experimental, Investigational
Sparfloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sparfloxacin.	Approved, Investigational
Spectinomycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Spectinomycin.	Approved, Investigational, Vet Approved
Spiramycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Spiramycin.	Approved
Squalamine	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Squalamine.	Investigational
Streptomycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Streptomycin.	Approved, Vet Approved
Sulbactam	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sulbactam.	Approved
Sulbenicillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sulbenicillin.	Experimental
Sulfacetamide	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sulfacetamide.	Approved
Sulfamerazine	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sulfamerazine.	Approved, Vet Approved
Sulfameter	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sulfameter.	Approved
Sulfamethoxypyridazine	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sulfamethoxypyridazine.	Experimental
Sulfanilamide	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sulfanilamide.	Approved
Sultamicillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sultamicillin.	Approved, Investigational
Talampicillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Talampicillin.	Experimental
Tazobactam	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tazobactam.	Approved
Tedizolid Phosphate	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tedizolid Phosphate.	Approved
Teicoplanin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Teicoplanin.	Approved, Investigational
Telavancin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Telavancin.	Approved
Telithromycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Telithromycin.	Approved
Temafloxacin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Temafloxacin.	Withdrawn
Temocillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Temocillin.	Approved, Investigational
Tetracycline	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tetracycline.	Approved, Vet Approved
Thalidomide	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Thalidomide.	Approved, Investigational, Withdrawn
Thiamphenicol	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Thiamphenicol.	Experimental, Investigational
Thiostrepton	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Thiostrepton.	Vet Approved
Thiosulfuric acid	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Thiosulfuric acid.	Approved, Investigational
Tiamulin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tiamulin.	Vet Approved
Ticarcillin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ticarcillin.	Approved, Investigational, Vet Approved
Tigecycline	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tigecycline.	Approved
Tilmicosin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tilmicosin.	Investigational, Vet Approved
Tobramycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tobramycin.	Approved, Investigational
Troleandomycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Troleandomycin.	Approved
Tunicamycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tunicamycin.	Experimental
Tylosin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tylosin.	Vet Approved
Tyrothricin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tyrothricin.	Approved
Ubenimex	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ubenimex.	Experimental, Investigational
Vancomycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Vancomycin.	Approved
Viomycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Viomycin.	Approved
Virginiamycin	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Virginiamycin.	Vet Approved
Virginiamycin M1	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Virginiamycin M1.	Experimental

Food Interactions

Not Available

References

General References

1. Nishikawa J, Kast A: Toxicity study with sodium picosulfate in cultured liver cells of rabbit, rat and man. Arzneimittelforschung. 1981;31(2):321-5. [PubMed:7194649]
2. Jauch R, Hammer R, Busch U, Kopitar Z, Ohnuma N, Niki T: [Pharmacokinetics and metabolism of sodium picosulfate in the rat (author's transl)]. Arzneimittelforschung. 1977;27(5):1045-50. [PubMed:577869]
3. Kim DH, Hyun SH, Shim SB, Kobashi K: The role of intestinal bacteria in the transformation of sodium picosulfate. Jpn J Pharmacol. 1992 May;59(1):1-5. [PubMed:1507649]
4. Love J, Bernard EJ, Cockeram A, Cohen L, Fishman M, Gray J, Morgan D: A multicentre, observational study of sodium picosulfate and magnesium citrate as a precolonoscopy bowel preparation. Can J Gastroenterol. 2009 Oct;23(10):706-10. [PubMed:19826647]
5. FDA Clinical Pharmacology and Biopharmaceutical Review(s) on PICOPREP [File]

External Links

PubChem Compound

5243

PubChem Substance

310265163

ChemSpider

5053

ChEMBL

CHEMBL1741134

Wikipedia

Sodium_picosulfate

ATC Codes

A06AB58 — Sodium picosulfate, combinations

• A06AB — Contact laxatives
• A06A — DRUGS FOR CONSTIPATION
• A06 — DRUGS FOR CONSTIPATION
• A — ALIMENTARY TRACT AND METABOLISM

A06AB08 — Sodium picosulfate

• A06AB — Contact laxatives
• A06A — DRUGS FOR CONSTIPATION
• A06 — DRUGS FOR CONSTIPATION
• A — ALIMENTARY TRACT AND METABOLISM

FDA label

Download (163 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Treatment	Healthy Volunteers	1
1, 2	Completed	Treatment	Need for Bowel Preparation	1
2	Completed	Screening	Healthy Volunteers	1
2	Recruiting	Diagnostic	Bowel Preperation / Polyethylene Glycol With Ascorbic Acid / Sodium Picosulfate and Magnesium Citrate	1
3	Completed	Not Available	Bowel preparation therapy	1
3	Completed	Other	Bowel preparation therapy	1
3	Completed	Treatment	Bowel preparation therapy	3
3	Completed	Treatment	Colonoscopy	1
3	Completed	Treatment	Occasional Constipation	1
3	Unknown Status	Diagnostic	Colonoscopy	1
4	Active Not Recruiting	Treatment	Patients Undergoing Elective Colonoscopy	1
4	Completed	Not Available	Bowel preparation therapy	1
4	Completed	Diagnostic	Colonoscopy	2
4	Completed	Diagnostic	Hemodynamics / Hyponatremias	1
4	Completed	Treatment	Cathartic Colon	1
4	Completed	Treatment	Colonoscopy	1
4	Not Yet Recruiting	Diagnostic	Bowel Preparation Solutions	1
4	Unknown Status	Treatment	Bowel Preparation Solutions / Endoscopy	1
Not Available	Completed	Not Available	Bowel Cleanliness	1
Not Available	Completed	Not Available	Colonoscopy Preparation	1
Not Available	Completed	Treatment	Inflammatory Bowel Diseases (IBD)	1
Not Available	Recruiting	Diagnostic	Colonoscopy	1
Not Available	Unknown Status	Diagnostic	Bowel preparation therapy	1
Not Available	Withdrawn	Screening	Patients Undergoing Screening or Surveillance Colonoscopy	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Form	Route	Strength
Liquid	Oral
Powder, for solution	Oral
Powder, metered	Oral

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US8450338	No	2008-10-10	2028-10-10
US8481083	No	2008-10-10	2028-10-10
US9827231	No	2014-06-23	2034-06-23

Properties

State

Solid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0185 mg/mL	ALOGPS
logP	-0.05	ALOGPS
logP	-1.5	ChemAxon
logS	-4.4	ALOGPS
pKa (Strongest Acidic)	-2.5	ChemAxon
pKa (Strongest Basic)	4.08	ChemAxon
Physiological Charge	-2	ChemAxon
Hydrogen Acceptor Count	7	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	140.09 Å2	ChemAxon
Rotatable Bond Count	7	ChemAxon
Refractivity	101.83 m3·mol-1	ChemAxon
Polarizability	40.3 Å3	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.

Kingdom

Organic compounds

Super Class

Benzenoids

Class

Benzene and substituted derivatives

Sub Class

Diphenylmethanes

Direct Parent

Diphenylmethanes

Alternative Parents

Phenylsulfates / Phenoxy compounds / Sulfuric acid monoesters / Pyridines and derivatives / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxidesHydrocarbon derivatives

show 1 more

Substituents

Diphenylmethane / Phenylsulfate / Arylsulfate / Phenoxy compound / Pyridine / Sulfuric acid monoester / Sulfate-ester / Sulfuric acid ester / Organic sulfuric acid or derivatives / Heteroaromatic compoundAzacycle / Organoheterocyclic compound / Hydrocarbon derivative / Organic oxide / Organopnictogen compound / Organooxygen compound / Organonitrogen compound / Organic oxygen compound / Organic nitrogen compound / Aromatic heteromonocyclic compound

show 10 more

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

Not Available

Drug created on October 27, 2015 21:06 / Updated on July 13, 2018 01:17